IGC-AD1 for Agitation in Alzheimer's Disease (NCT05543681)

ClinicalTrials.gov Identifier: [NCT05543681](https://clinicaltrials.gov/study/NCT05543681)

Trial Overview

| Attribute | Details |
|-----------|---------|
| Phase | Phase 1 |
| Status | Recruiting / Active |
| Sponsor | IGC Pharma |
| Intervention | IGC-AD1 (cannabinoid-based therapeutic) |
| Indication | Agitation in Alzheimer's Disease |
| Study Design | Parallel assignment |

Mechanism of Action

ClinicalTrials.gov Identifier: [NCT05543681](https://clinicaltrials.gov/study/NCT05543681)

Trial Overview

| Attribute | Details |
|-----------|---------|
| Phase | Phase 1 |
| Status | Recruiting / Active |
| Sponsor | IGC Pharma |
| Intervention | IGC-AD1 (cannabinoid-based therapeutic) |
| Indication | Agitation in Alzheimer's Disease |
| Study Design | Parallel assignment |

Mechanism of Action

IGC-AD1 is a cannabinoid-based therapeutic designed to modulate the endocannabinoid system to reduce agitation in Alzheimer's disease patients. The mechanism involves:

Endocannabinoid System Modulation

The endocannabinoid system plays a critical role in regulating emotional responses, anxiety, and behavioral symptoms. IGC-AD1 acts on:

• Cannabinoid type 1 (CB1) receptors — Predominantly expressed in the brain, particularly in regions involved in emotional regulation such as the amygdala and prefrontal cortex. CB1 receptor activation can reduce anxiety and agitation[@busquetsgarcia2014]
• Cannabinoid type 2 (CB2) receptors — Expressed primarily on immune cells including microglia. CB2 receptor modulation may reduce neuroinflammation, which is increasingly recognized as a contributor to behavioral symptoms in Alzheimer's disease[@fernndezruiz2015]

Rationale for Alzheimer's Agitation

Agitation is one of the most common and challenging behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease, affecting up to 70% of patients during the disease course[@cerejeira2012]. Current treatment options are limited:

• Antipsychotics — Associated with increased mortality, stroke, and cognitive decline
• benzodiazepines — Risk of falls, worsening cognition, and dependence
• Non-pharmacological approaches — Limited efficacy in moderate to severe agitation

Study Design

As a Phase 1 trial, IGC-AD1 is primarily focused on:

• Safety and tolerability — Determining the safety profile and maximum tolerated dose
• Pharmacokinetics — How the drug is absorbed, distributed, metabolized, and excreted
• Preliminary efficacy signals — Early evidence of effectiveness for reducing agitation

Expected Outcomes

Phase 1 trials typically evaluate:

• Adverse events and serious adverse events
• Dose-limiting toxicities
• Optimal dosing regimen for Phase 2 studies
• Preliminary measures of agitation reduction using validated scales (e.g., Cohen-Mansfield Agitation Inventory)

Clinical Context

Comparison to Other Cannabinoid Trials for Alzheimer's Agitation

IGC-AD1 enters a growing field of cannabinoid-based approaches for Alzheimer's agitation:

| Trial | Compound | Phase | Status |
|-------|----------|-------|--------|
| NAB-IT (NCT04516057) | Nabilone (synthetic THC) | Phase 3 | Recruiting |
| IGC-AD1 (NCT05543681) | IGC-AD1 | Phase 1 | Active |
| Various CBD trials | Cannabidiol | Phase 2/3 | Various |

IGC-AD1 represents a potentially novel cannabinoid formulation that may differ from existing synthetic cannabinoids like nabilone or dronabinol. The specific formulation may include multiple cannabinoid compounds rather than single-molecule approaches.

Company's Pipeline

IGC Pharma is developing a portfolio of cannabinoid-based therapeutics:

• IGC-AD1 — Furthest along in clinical development (Phase 1)
• CALMA — Phase 2 trial (likely for Alzheimer's agitation)
• Pre-clinical candidates — Additional pipeline compounds

Safety Considerations

Cannabinoid-based therapies have a generally favorable safety profile compared to antipsychotics, but monitoring is still essential:

• Cognitive effects: Must assess for any impact on cognition
• Sedation: Monitor for excessive drowsiness
• Cardiovascular: Track heart rate and blood pressure
• Drug interactions: Review concomitant medications
• Psychiatric: Monitor for mood changes or anxiety

Regulatory Pathway

Cannabinoid-based therapeutics face unique regulatory considerations:

• Schedule status: Cannabinoids may have controlled substance classification that affects development
• Standardized formulations: Ensuring consistent dosing across batches
• Combination products: May require additional regulatory considerations
• Approval history: Sativex (nabiximols) provides precedent for plant-derived cannabinoid approval in other indications

• Agitation in Alzheimer's Disease
• [Endocannabinoid System in Neurodegeneration](/diseases/neurodegeneration)](/diseases/neurodegeneration)
• [Endocannabinoid Signaling in Neurodegeneration](/genes/gnal)](/genes)
• [Cannabinoid Receptor Modulation Therapy](/therapeutics/cannabinoid-receptor-modulation-therapy)
• NAB-IT: Nabilone for Agitation in Alzheimer's Disease
• [CNR2 — Cannabinoid Receptor 2](/genes/cnr2)

External Links

• [ClinicalTrials.gov: NCT05543681](https://clinicaltrials.gov/study/NCT05543681)
• [IGC Pharma Pipeline](https://www.igcpharma.com/pipeline)

References